Recent Advances in Nanomedicines for Multiple Sclerosis Therapy | ACS Applied Bio Materials
Interferons at age 50: past, current and future impact on biomedicine | Nature Reviews Drug Discovery
The innovative development in interferon beta treatments of relapsing‐remitting multiple sclerosis - Madsen - 2017 - Brain and Behavior - Wiley Online Library
Differential mechanisms of action of interferon-β and glatiramer acetate in MS | Neurology
Multiple Sclerosis | NEJM
Mechanism of Action of Interferon Beta in Treatment of Multiple Sclerosis - ScienceDirect
Selective Targeting of T and B Cell Populations by Alemtuzumab in the Treatment of Multiple Sclerosis - touchNEUROLOGY
Pharmacogenomic update on multiple sclerosis: a focus on actual and new therapeutic strategies | The Pharmacogenomics Journal
Mechanism of Action of Interferon Beta in Treatment of Multiple Sclerosis - ScienceDirect
Cells | Free Full-Text | The Meaning of Immune Reconstitution after Alemtuzumab Therapy in Multiple Sclerosis | HTML
Interferon Beta Expression in MS | How Rebif® (interferon beta-1a) Works | HCPs
Frontiers | Multiple Sclerosis and Cancer: The Ying-Yang Effect of Disease Modifying Therapies | Immunology
Mechanism of Action of Interferon Beta in Treatment of Multiple Sclerosis - ScienceDirect
Therapies for multiple sclerosis: translational achievements and outstanding needs: Trends in Molecular Medicine
Current immunotherapies for multiple sclerosis and neuromyelitis optica spectrum disorders: the similarities and differences
Proposed Mechanism of Action (MOA) | OCREVUS® (ocrelizumab)
Mechanism of action of alemtuzumab. (a) Cellular targets of alemtuzumab... | Download Scientific Diagram
The Mechanism of Action of Interferon-β in Relapsing Multiple Sclerosis | SpringerLink
Acting centrally or peripherally: A renewed interest in the central nervous system penetration of disease-modifying drugs in multiple sclerosis - Multiple Sclerosis and Related Disorders
Interferon-β mechanisms of action in multiple sclerosis | Neurology
Cells | Free Full-Text | Lymphocyte Counts and Multiple Sclerosis Therapeutics: Between Mechanisms of Action and Treatment-Limiting Side Effects | HTML
Two decades of subcutaneous glatiramer acetate injection: current role | PPA
Mechanism of Action of Interferon Beta in Treatment of Multiple Sclerosis - ScienceDirect
Back to the future for multiple sclerosis therapy: focus on current and emerging disease-modifying therapeutic strategies | Immunotherapy
